5:15 PM ET
8-K
Divestiture
BioXcel Therapeutics Divestiture to Teva Pharmaceuticals International GmbH for $57.5M
BioXcel Therapeutics completed the sale of substantially all of its neuroscience assets, including IGALMI and BXCL501, to Teva Pharmaceuticals for $57.5 million in upfront cash. The company is also eligible for up to $67.5 million in development milestones and $20 million in commercial milestones. The sale was conducted under Section 363 of the Bankruptcy Code as part of BioXcel's Chapter 11 proceedings.
- Value
- $57.5M
- Counterparty
- Teva Pharmaceuticals International GmbH